Atopic DermatitisSymptoms, Doctors, Treatments, Advances & More
Atopic Dermatitis Overview
Learn About Atopic Dermatitis
James W. Baker MD LLC
Andrew Blauvelt is a Dermatologist practicing medicine in Portland, Oregon. Dr. Blauvelt is rated as an Elite provider by MediFind in the treatment of Atopic Dermatitis. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Actinic Keratosis. Dr. Blauvelt is currently accepting new patients.
SSM Health Cardinal Glennon Pediatrics Specialty Services - Grand Boulevard
Elaine Siegfried is a Dermatologist and a Pediatrics provider practicing medicine in St. Louis, Missouri. Dr. Siegfried is rated as an Elite provider by MediFind in the treatment of Atopic Dermatitis. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Atopic Dermatitis, Molluscum Contagiosum, Harlequin Ichthyosis, and Ectodermal Dysplasias. Dr. Siegfried is board certified in American Board Of Dermatology/Pediatric Dermatology , American Board Of Dermatology , and Missouri State Board Of Registration. Dr. Siegfried is currently accepting new patients.
Psoriasis And Skin Treatment Center
Wilson Liao is a Dermatologist practicing medicine in San Francisco, California. Dr. Liao is rated as an Elite provider by MediFind in the treatment of Atopic Dermatitis. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Psoriasis, Plaque Psoriasis, Atopic Dermatitis, Guttate Psoriasis, and Tissue Biopsy. Dr. Liao is board certified in American Board Of Dermatology, Dermatology. Dr. Liao is currently accepting new patients.
Summary: This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Summary: This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Peri...

